EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular Signatures of Blood Biomarkers in Depression: Gene Expression Analysis of GAR1, PER3, MTPAP, SLC25A26, and CD19, a Case–Control Study

Molekulare Signaturen von Blut-Biomarkern bei Depression: Genexpressionsanalyse von GAR1, PER3, MTPAP, SLC25A26 und CD19, Fall-Kontroll-Studie

Remya Bhaskaran S iD, Ramya Sugumar iD, Suvarna Jyothi Kantipudi, C D Mohana Priya, C Sheela Sasikumar

Diagnostics · 16.03.2026 · 16 (6) · 884

DOI: 10.3390/diagnostics16060884 ↗

Auf einen Blick

Bei 100 unbehandelten MDD-Patient:innen und 100 Kontrollen wurden CD19, MTPAP und PER3 im peripheren Blut erhöht gefunden. Die kombinierte ROC-Analyse ergab eine AUC von 0,885.

Fragestellung

Unterscheidet die Genexpression von CD19, MTPAP, PER3, GAR1 und SLC25A26 im peripheren Blut drug-naïve MDD-Patient:innen von gesunden Kontrollen?

Methode

Fall-Kontroll-Studie; peripheres Blut von 100 neu diagnostizierten, drug-naïven MDD-Patient:innen und 100 alters- und geschlechtsabgeglichenen Kontrollen; qRT-PCR, t-Tests, ANOVA, ROC-Analyse.

Ergebnisse

CD19 (fold change 6,15; p = 6,17 × 10−10), MTPAP (3,99; p = 1,74 × 10−8) und PER3 (2,42; p = 5,33 × 10−6) waren erhöht. GAR1 (1,26; p = 0,47) und SLC25A26 (1,24; p = 0,47) nicht signifikant verändert.

Schlussfolgerung der Autor:innen

Die Autor:innen sehen CD19, MTPAP und PER3 als vielversprechende periphere Blut-Biomarker für MDD mit möglicher Bedeutung für frühe Diagnose, Schweregradeinschätzung und personalisierte Therapie.

Kernaussagen

  • CD19, MTPAP und PER3 waren bei MDD erhöht
  • Kombinierte ROC-Analyse: AUC 0,885
  • Genexpression korrelierte mit HAM-D und PHQ-9

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Diagnostics, online erschienen am 16.03.2026. Verfasst von Remya Bhaskaran S und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Sri Ramachandra Institute of Higher Education and Research (SRIHER), Porur, Chennai 600116, India. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objective: Major depressive disorder (MDD) is a common mental illness that lacks objective diagnostic biomarkers and has a complicated pathogenesis. Peripheral blood-based gene expression profiling provides a potential, non-invasive method to identify the molecular markers associated with risk stratification and depression severity.This study aimed to investigate the gene expression of five candidate genes—CD19, MTPAP, PER3, GAR1, and SLC25A26—in the peripheral blood of drug-naïve patients with MDD and to evaluate their potential as diagnostic biomarkers.

Methods

Peripheral blood samples were collected from 100 newly diagnosed, drug-naïve MDD patients and 100 age- and sex-matched healthy controls. The total RNA was extracted and reverse-transcribed for quantitative real-time PCR analysis. Fold change and ∆∆Ct values were calculated for each gene, followed by statistical analysis using t-tests and ANOVA. Receiver operating characteristic (ROC) curves were used to evaluate diagnostic performance. Gene co-expression and pathway enrichment analyses were conducted to explore functional relevance.

Results

Significant upregulation was observed for CD19 (fold change = 6.15, p = 6.17 × 10−10), MTPAP (fold change = 3.99, p = 1.74 × 10−8), and PER3 (fold change = 2.42, p = 5.33 × 10−6) in MDD. GAR1 showed modest upregulation (fold change = 1.26, p = 0.47), while SLC25A26 (fold change = 1.24, p = 0.47) was not significantly altered. Combined ROC analysis yielded an AUC of 0.885, indicating a strong discriminative ability. Gene expression correlated with depression severity (HAM-D and PHQ-9).

Conclusions

This study identifies CD19, MTPAP, and PER3 as promising peripheral blood biomarkers for MDD, with potential implications for early diagnosis, severity assessment, and personalized treatment strategies.

Schlagwörter

Stichwörter der Autor:innen

CD19MTPAPPER3ROC analysisbiomarkersgene expressionmajor depressive disordermental healthmental wellnessperipheral bloodpsychiatric diagnosisqRT-PCR

Autor:innen und Institutionen

  • Department of Pharmacology, Sri Ramachandra Institute of Higher Education and Research (SRIHER), Porur, Chennai 600116, India.
  • Department of Psychiatry, Sri Ramachandra Institute of Higher Education and Research (SRIHER), Porur, Chennai 600116, India.
  • Department of Human Genetics, Sri Ramachandra Institute of Higher Education and Research (SRIHER), Porur, Chennai 600116, India.
  • Dr. RK Diabetic Foot and Podiatric Institute & Rakesh Jhunjhunwala Amputation Prevention Centre, Chennai 600099, India.

ORCID-Profile: Remya Bhaskaran S, Ramya Sugumar

Zitieren

APA

S, R. B., Sugumar, R., Kantipudi, S. J., Priya, C. D. M., & Sasikumar, C. S. (2026). Molecular Signatures of Blood Biomarkers in Depression: Gene Expression Analysis of GAR1, PER3, MTPAP, SLC25A26, and CD19, a Case–Control Study. Diagnostics, 16(6), 884. https://doi.org/10.3390/diagnostics16060884

Vancouver

S RB, Sugumar R, Kantipudi SJ, Priya CDM, Sasikumar CS. Molecular Signatures of Blood Biomarkers in Depression: Gene Expression Analysis of GAR1, PER3, MTPAP, SLC25A26, and CD19, a Case–Control Study. Diagnostics. 2026;16(6):884. doi:10.3390/diagnostics16060884

BibTeX
@article{S2026,
  author = {S, Remya Bhaskaran and Sugumar, Ramya and Kantipudi, Suvarna Jyothi and Priya, C D Mohana and Sasikumar, C Sheela},
  title = {Molecular Signatures of Blood Biomarkers in Depression: Gene Expression Analysis of GAR1, PER3, MTPAP, SLC25A26, and CD19, a Case–Control Study},
  journal = {Diagnostics},
  year = {2026},
  volume = {16},
  number = {6},
  pages = {884},
  doi = {10.3390/diagnostics16060884}
}
Kostenlos starten →